{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:11:39Z","timestamp":1790068299311,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA195149"],"award-info":[{"award-number":["R21CA195149"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RO1CA190223"],"award-info":[{"award-number":["RO1CA190223"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11060-018-03009-7","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T14:43:46Z","timestamp":1541774626000},"page":"529-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma"],"prefix":"10.1007","volume":"140","author":[{"given":"Christine G.","family":"Skibinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9634-8524","authenticated-orcid":false,"given":"Gregory J.","family":"Riggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"issue":"Suppl 4","key":"3009_CR1","doi-asserted-by":"publisher","first-page":"iv1iv62","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2008\u20132012. Neuro Oncol 17(Suppl 4):iv1\u2013iv62","journal-title":"Neuro Oncol"},{"key":"3009_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fsurg.2016.00040","volume":"3","author":"WL Bi","year":"2016","unstructured":"Bi WL et al (2016) Meningioma genomics: diagnostic, prognostic, and therapeutic applications. Front Surg 3:40","journal-title":"Front Surg"},{"key":"3009_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.wneu.2017.01.070","volume":"101","author":"RA Kessler","year":"2017","unstructured":"Kessler RA et al (2017) Metastatic atypical and anaplastic meningioma: a case series and review of the literature. World Neurosurg 101:47\u201356","journal-title":"World Neurosurg"},{"issue":"6","key":"3009_CR4","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.3171\/2013.10.FOCUS13341","volume":"35","author":"AA Moazzam","year":"2013","unstructured":"Moazzam AA, Wagle N, Zada G (2013) Recent developments in chemotherapy for meningiomas: a review. Neurosurg Focus 35(6):E18","journal-title":"Neurosurg Focus"},{"issue":"3","key":"3009_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2217\/cns.13.17","volume":"2","author":"MC Chamberlain","year":"2013","unstructured":"Chamberlain MC (2013) IFN-alpha for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. CNS Oncol 2(3):227\u2013235","journal-title":"CNS Oncol"},{"issue":"10","key":"3009_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","volume":"69","author":"MC Chamberlain","year":"2007","unstructured":"Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurol 69(10):969\u2013973","journal-title":"Neurol"},{"issue":"1","key":"3009_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","volume":"109","author":"E Lou","year":"2012","unstructured":"Lou E et al (2012) Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series. J Neurooncol 109(1):63\u201370","journal-title":"J Neurooncol"},{"issue":"12","key":"3009_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s00432-013-1539-5","volume":"139","author":"P Nygren","year":"2013","unstructured":"Nygren P et al (2013) Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J Cancer Res Clin Oncol 139(12):2133\u20132140","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"3009_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/0284186X.2013.844359","volume":"53","author":"P Nygren","year":"2014","unstructured":"Nygren P, Larsson R (2014) Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer. Acta Oncol 53(3):427\u2013428","journal-title":"Acta Oncol"},{"issue":"6","key":"3009_CR10","first-page":"1264","volume":"45","author":"K Sawanyawisuth","year":"2014","unstructured":"Sawanyawisuth K et al (2014) Effect of the antiparasitic drug mebendazole on cholangiocarcinoma growth. SE Asian J Trop Med Public Health 45(6):1264\u20131270","journal-title":"SE Asian J Trop Med Public Health"},{"issue":"1","key":"3009_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12920-016-0212-7","volume":"9","author":"HR Chen","year":"2016","unstructured":"Chen HR et al (2016) A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med Genomics 9(1):51","journal-title":"BMC Med Genomics"},{"issue":"6","key":"3009_CR12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.eururo.2016.07.015","volume":"70","author":"S Gillessen","year":"2016","unstructured":"Gillessen S et al (2016) Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform. Eur Urol 70(6):906\u2013908","journal-title":"Eur Urol"},{"issue":"12","key":"3009_CR13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/2159-8290.CD-13-0183","volume":"3","author":"NS Jahchan","year":"2013","unstructured":"Jahchan NS et al (2013) A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 3(12):1364\u20131377","journal-title":"Cancer Discov"},{"issue":"1","key":"3009_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/MOG.0000000000000025","volume":"30","author":"TR McCarty","year":"2014","unstructured":"McCarty TR, Turkeltaub JA, Hotez PJ (2014) Global progress towards eliminating gastrointestinal helminth infections. Curr Opin Gastroenterol 30(1):18\u201324","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"3009_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/00034983.1999.11813432","volume":"93","author":"K Vutova","year":"1999","unstructured":"Vutova K et al (1999) Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration. Ann Trop Med Parasitol 93(4):357\u2013365","journal-title":"Ann Trop Med Parasitol"},{"issue":"2","key":"3009_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0001-706X(02)00217-6","volume":"85","author":"J El-On","year":"2003","unstructured":"El-On J (2003) Benzimidazole treatment of cystic echinococcosis. Acta Trop 85(2):243\u2013252","journal-title":"Acta Trop"},{"issue":"9","key":"3009_CR17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nor077","volume":"13","author":"RY Bai","year":"2011","unstructured":"Bai RY et al (2011) Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol 13(9):974\u2013982","journal-title":"Neuro Oncol"},{"issue":"42","key":"3009_CR18","doi-asserted-by":"publisher","first-page":"68571","DOI":"10.18632\/oncotarget.11851","volume":"7","author":"T Williamson","year":"2016","unstructured":"Williamson T et al (2016) Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. Oncotarget 7(42):68571\u201368584","journal-title":"Oncotarget"},{"issue":"8","key":"3009_CR19","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/1541-7786.MCR-07-2159","volume":"6","author":"N Doudican","year":"2008","unstructured":"Doudican N et al (2008) Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 6(8):1308\u20131315","journal-title":"Mol Cancer Res"},{"issue":"13","key":"3009_CR20","first-page":"1201","volume":"1","author":"J Sasaki","year":"2002","unstructured":"Sasaki J et al (2002) The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 1(13):1201\u20131209","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"3009_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/neuonc\/nou234","volume":"17","author":"RY Bai","year":"2015","unstructured":"Bai RY et al (2015) Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro Oncol 17(4):545\u2013554","journal-title":"Neuro Oncol"},{"issue":"1","key":"3009_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-14-0755-T","volume":"14","author":"AR Larsen","year":"2015","unstructured":"Larsen AR et al (2015) Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Mol Cancer Ther 14(1):3\u201313","journal-title":"Mol Cancer Ther"},{"issue":"15","key":"3009_CR23","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-14-2681","volume":"21","author":"RY Bai","year":"2015","unstructured":"Bai RY et al (2015) Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model. Clin Cancer Res 21(15):3462\u20133470","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3009_CR24","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s12032-014-0866-y","volume":"31","author":"M Buglione","year":"2014","unstructured":"Buglione M et al (2014) Role of external beam radiotherapy in the treatment of relapsing meningioma. Med Oncol 31(3):866","journal-title":"Med Oncol"},{"issue":"4","key":"3009_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1227\/NEU.0000000000000462","volume":"75","author":"SQ Sun","year":"2014","unstructured":"Sun SQ et al (2014) Management of atypical cranial meningiomas, part 2: predictors of progression and the role of adjuvant radiation after subtotal resection. Neurosurg. 75(4):356\u2013363. (discussion 363)","journal-title":"Neurosurg"},{"key":"3009_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.canlet.2017.11.035","volume":"415","author":"WS Ho","year":"2018","unstructured":"Ho WS et al (2018) LB-100, a novel protein phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett 415:217\u2013226","journal-title":"Cancer Lett"},{"issue":"4","key":"3009_CR27","first-page":"809","volume":"36","author":"V Rao Gogineni","year":"2010","unstructured":"Rao Gogineni V et al (2010) Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma. Int J Oncol 36(4):809\u2013816","journal-title":"Int J Oncol"},{"issue":"19","key":"3009_CR28","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1158\/1078-0432.CCR-12-0299","volume":"19","author":"A Wilisch-Neumann","year":"2013","unstructured":"Wilisch-Neumann A et al (2013) The integrin inhibitor cilengitide affects meningioma cell motility and invasion. Clin Cancer Res 19(19):5402\u20135412","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3009_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11060-005-9076-y","volume":"78","author":"GS Baia","year":"2006","unstructured":"Baia GS et al (2006) A genetic strategy to overcome the senescence of primary meningioma cell cultures. J Neurooncol 78(2):113\u2013121","journal-title":"J Neurooncol"},{"issue":"7","key":"3009_CR30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1158\/1541-7786.MCR-12-0116","volume":"10","author":"GS Baia","year":"2012","unstructured":"Baia GS et al (2012) Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res 10(7):904\u2013913","journal-title":"Mol Cancer Res"},{"issue":"11","key":"3009_CR31","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1593\/neo.08642","volume":"10","author":"K Striedinger","year":"2008","unstructured":"Striedinger K et al (2008) The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 10(11):1204\u20131212","journal-title":"Neoplasia"},{"issue":"1","key":"3009_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-014-1422-5","volume":"118","author":"AS Yamashita","year":"2014","unstructured":"Yamashita AS et al (2014) Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors. J Neurooncol 118(1):83\u201392","journal-title":"J Neurooncol"},{"issue":"6","key":"3009_CR33","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1158\/1078-0432.CCR-05-1803","volume":"12","author":"K Hasegawa","year":"2006","unstructured":"Hasegawa K et al (2006) Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 12(6):1868\u20131875","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3009_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1750-3639.2007.00109.x","volume":"18","author":"GS Baia","year":"2008","unstructured":"Baia GS et al (2008) An orthotopic skull base model of malignant meningioma. Brain Pathol 18(2):172\u2013179","journal-title":"Brain Pathol"},{"issue":"5","key":"3009_CR35","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.ijrobp.2008.04.025","volume":"71","author":"J Wong","year":"2008","unstructured":"Wong J et al (2008) High-resolution, small animal radiation research platform with X-ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys 71(5):1591\u20131599","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3009_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1413.001","volume":"1131","author":"P Baluk","year":"2008","unstructured":"Baluk P, McDonald DM (2008) Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Ann N Y Acad Sci 1131:1\u201312","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"3009_CR37","doi-asserted-by":"publisher","first-page":"101042831769552","DOI":"10.1177\/1010428317695528","volume":"39","author":"GL Gravina","year":"2017","unstructured":"Gravina GL et al (2017) The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumour Biol 39(6):1010428317695528","journal-title":"Tumour Biol"},{"issue":"27","key":"3009_CR38","doi-asserted-by":"publisher","first-page":"42408","DOI":"10.18632\/oncotarget.9878","volume":"7","author":"CJ Lin","year":"2016","unstructured":"Lin CJ et al (2016) Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis. Oncotarget 7(27):42408\u201342421","journal-title":"Oncotarget"},{"issue":"2","key":"3009_CR39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nec.2015.11.002","volume":"27","author":"M Karsy","year":"2016","unstructured":"Karsy M et al (2016) Medical management of meningiomas: current status, failed treatments, and promising horizons. Neurosurg Clin N Am 27(2):249\u2013260","journal-title":"Neurosurg Clin N Am"},{"key":"3009_CR40","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.2147\/OTT.S143096","volume":"10","author":"D Markowitz","year":"2017","unstructured":"Markowitz D et al (2017) Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism. Onco Targets Ther 10:5633\u20135642","journal-title":"Onco Targets Ther"},{"issue":"5","key":"3009_CR41","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1073\/pnas.1416418112","volume":"112","author":"MS Poruchynsky","year":"2015","unstructured":"Poruchynsky MS et al (2015) Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc Natl Acad Sci USA 112(5):1571\u20131576","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-03009-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-03009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-03009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:32:08Z","timestamp":1589700728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-03009-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3009"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-03009-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"18 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Riggins is a founder of and holds equity in Benizole Therapeutics PBC. The results of the study discussed in this publication could affect the value of Benizole. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. GJR has a financial interest in Benizole Therapeutics, PBC and in mebendazole related intellectual property managed by Johns Hopkins University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Rodent experiments were performed using a protocol approved by the Johns Hopkins University Institutional Animal Care and Use Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}